Michelson Diagnostics Ltd. was formed in March 2006 by five physicists and engineers and is the world leader in practical OCT dermatology applications. Our flagship product, VivoSight Dx, is a state-of-the art Optical Coherence Tomography (OCT) system. It is a powerful, non-invasive and versatile imaging tool that provides objective measurement of multiple parameters in skin research and for advanced clinical practice.
We believe in medical imaging & measurements to be a fundamental procedure leading to new discoveries, understanding and ultimately better treatments with unique products. VivoSight has been cited in over 350 peer reviewed publications.
Our purpose is to realize highly cost-effective, unique OCT applications for everyday use in skin research facilities and dermatology practices. VivoSight images and measurements can provide researchers and clinicians with valuable information that can help them deliver Healthy Skin for Happy Living.
Together with our stakeholders, we nurture curiosity and collaboration to explore meaningful frontiers and gain a better understanding of The Whole Picture that VivoSight OCT images provide.
Company’s Keywords:
biotechnology, life sciences, optical coherence tomography, microneedles, transdermal, atopic dermatitis, drug delivery, eczema, skin cancer, basal cell carcinoma, port wine stain, dermatology, medical imaging technology, diagnosis & monitoring of skin conditions, vascular imaging, vivosight, oct
<10
<7100000
<2006